olaparib
Selected indexed studies
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. (N Engl J Med, 2017) [PMID:28578601]
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. (Lancet Oncol, 2017) [PMID:28754483]
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. (N Engl J Med, 2018) [PMID:30345884]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer. (2022) pubmed
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. (2017) pubmed
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. (2017) pubmed
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. (2018) pubmed
- Olaparib. (2018) pubmed
- OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. (2019) pubmed
- Olaparib for advanced breast cancer. (2020) pubmed
- Olaparib synergizes with arsenic trioxide by promoting apoptosis and ferroptosis in platinum-resistant ovarian cancer. (2022) pubmed
- Olaparib: A Review as First-Line Maintenance Therapy in Advanced Ovarian Cancer. (2021) pubmed
- Olaparib: A Chemosensitizer for the Treatment of Glioblastoma. (2025) pubmed